February is recognized as Cancer Prevention Month, with World Cancer Day on February 4 serving as a global reminder that improving outcomes in cancer depends on earlier detection, better diagnostics, and faster translation of data into clinical decisions. In precision oncology, early detection no longer stops at identifying the presence of cancer but increasingly depends on detecting the right genomic… Read more »
February is Cancer Prevention Month, a timely reminder that the most effective cancer intervention often happens long before a diagnosis is ever made. For decades, prevention has focused on lifestyle guidance and population-level screening. While important, these approaches overlook a critical reality: cancer risk is highly individualized. Genetics, molecular biology, and drug response all shape who is at risk, when… Read more »
When it comes to cervical cancer, early detection and timely analysis can literally be life-saving. Cervical cancer is the fourth most common cancer in women worldwide, with an estimated 660,000 new cases and around 350,000 deaths each year. Early detection through screening and quick diagnostic support drastically improves outcomes because, when caught early, cervical cancer is among the most preventable… Read more »
Diffuse midline glioma (DMG) is one of the most urgent unmet needs in neuro-oncology. This rare, aggressive brain cancer primarily affects children and arises in critical midline structures of the brain, such as the brainstem and thalamus, where surgery is not feasible, and treatment options are severely limited. Its diffuse growth and defining molecular drivers, such as H3-3A K27M, make… Read more »
Golden Helix’s VSClinical AMP guidelines platform, powered by our Golden Helix CancerKB has long been trusted by clinicians and researchers for generating report-ready clinical cancer biomarker interpretations. To further elevate the coverage and currency of our somatic variant evaluation capabilities, we’ve integrated Genomenon’s Cancer Knowledgebase (CKB) into both VarSeq and VSClinical AMP. This partnership represents a significant enhancement in somatic… Read more »
Precision oncology moves fast, and labs need tools that can keep up. Golden Helix CancerKB is built for clinical labs that want high-quality, report-ready cancer interpretations without the manual workload or inconsistencies that slow teams down. Stay in the Loop with Golden Helix CancerKB Oncology doesn’t stand still and neither does Golden Helix CancerKB. Our in-house curation team continually reviews… Read more »
As precision oncology evolves, clinicians and laboratories need tools that can both handle massive genomic datasets and translate those findings into clear, clinically actionable guidance. In our recent webcast, “Simplifying Complex Cancer Data into Actionable Knowledge with Golden Helix CancerKB,” we walked through how Golden Helix CancerKB can take clinical somatic variant analysis to the next level within VSClinical AMP…. Read more »
In recent years, the adoption of advanced bioinformatics platforms has enabled clinicians and researchers to identify novel variants, characterize complex inheritance patterns, and better understand the clinical impact of genetic disorders. Below are publications from customers in September 2025, showcasing the work built upon the trusted capabilities of our VarSeq and VS-CNV software to annotate, filter, and interpret genomic variants… Read more »
At Golden Helix, we get to see firsthand how our software enables groundbreaking research around the world. Our tools are central to real-world discoveries, from cancer studies and prenatal diagnostics to uncovering new genetic links in rare diseases. These publications from August 2025 showcase how VarSeq and VSPipeline are helping researchers push the boundaries of what’s possible—automating workflows, streamlining variant… Read more »
This year, the Golden Helix CancerKB curation team has been hard at work expanding and refining the content that supports cancer variant interpretation and clinical reporting. In addition to staying current with the latest FDA-approved therapies and NCCN Guideline-recommended treatments, the team has taken on a significant new initiative: developing comprehensive diagnostic and prognostic interpretation summaries for the most prominent… Read more »
This month, our team at Golden Helix is proud to highlight a series of standout customer publications demonstrating the real-world impact of next-generation sequencing and variant analysis. Featured articles from June 2025 showcase the power of the VarSeq platform in supporting high-quality research across hereditary and somatic disease. From integrating AI to enhance variant detection in colorectal cancer, to reclassifying… Read more »
Just in time for the holidays, Golden Helix CancerKB 4.0 is now available to incorporate into your cancer analysis workflows! We have termed this release “The Hematological release” as we boast of complete coverage of the NCCN Guidelines recommended therapies and FDA-approved therapies for all hematological cancers in our Drug Sensitivity Interpretations. We have also reviewed and synthesized the consensus… Read more »
Exome and genome sequencing have advanced genetic research, but data analysis remains complex. VarSeq simplifies this by helping researchers identify key genetic changes in rare diseases and cancer, improving screening and diagnosis. Here are recent customer publications that highlight VarSeq usage. Expanded carrier screening for inherited genetic disease using exome and genome sequencing The goal of this study was to… Read more »
You might have noticed an uptick in the number of interpretations associated with hematological cancers within the Golden Helix CancerKB database over the past several months. This is because the Golden Helix CancerKB curation team has been focused on bolstering our drug sensitivity, diagnostic, and prognostic interpretations. This project has had the team reading through the NCCN Guidelines, WHO Guidelines… Read more »
The FDA approved the first medical therapy for desmoid tumors only a few months ago! What’s the big deal, right? Desmoid tumors are non-cancerous and can’t even metastasize. Well, in this blog post, I want to discuss these interesting tumors, and you will find that not only are these tumors anything but benign, but Golden Helix CancerKB has you covered… Read more »
Thank you to all our viewers who attended our webcast last week on VarSeq 2.5.0: VSClinical AMP Workflow from the User Perspective. Overall, this webcast highlighted the versatility of VarSeq, demonstrating both a Tumor-Normal somatic workflow and a singleton somatic analysis. In addition, we got to see the utility of our new cancer classifier and the upgrades to our Golden… Read more »
I am very excited to announce that a new version of Golden Helix CancerKB has been released! This new version of Golden Helix CancerKB comes with some exciting upgrades bolstering the gene interpretations and cancer gene evidence. Before I jump into the details of the new information that is now in Golden Helix CancerKB, I want to give everyone a… Read more »
In an era where genetics is reshaping our understanding of diseases, recent customer research publications offer invaluable insights, particularly in the realm of cancer. A study titled “Co-Occurrence of Germline Genomic Variants and Copy Number Variations in Hereditary Breast and Colorectal Cancer Patients” dives into a rare phenotype bridging hereditary colorectal and breast cancer syndromes, revealing the profound impact of… Read more »
While the analysis of gene fusions is crucial for understanding the genetic basis of cancer, the process of interpreting these mutations can be challenging. One important component of fusion interpretation is the identification of relevant publications. To aid researchers in the search for publications related to specific gene fusions, Felix Mitelman and colleagues have created the Mitelman Database of Chromosome… Read more »
Our team at Golden Helix remains committed to advancing genomics and personalized medicine. We actively participate in industry conferences to stay current with the latest developments, such as the recent ACMG 2023 in Salt Lake City, Utah. This event facilitated valuable insights and discussions on several topics. Three key areas of focus included: Whole Exome Sequencing: Whole Exome Sequencing (WES)… Read more »
